only a small fraction of the estimated heritability of BP saltsensitivity. Resequencing studies focusing on low-frequency and rare variants, which are commonly excluded in traditional genome-wide association and candidate gene studies, could further delineate the genomic underpinnings of BP salt-sensitivity. 22 In the first resequencing study of the BP salt-sensitivity phenotype, we aimed to identify novel common, low-frequency and rare variants from 7 RAAS genes associated with BP salt-sensitivity. This unique research leveraged carefully collected data from a family-based dietary sodium feeding study conducted among participants of the Genetic Epidemiology Network of Salt-Sensitivity (GenSalt) study. Using aggregate rare variant and single-marker analyses, we compared the frequencies of identified variants between the 300 most salt-sensitive and 300 most salt-resistant GenSalt participants after adjustment for important covariables.
METHODS

Study population
The GenSalt study was conducted among a Han Chinese population with habitually high-sodium intake from rural, north China. 23, 24 A community based BP screening was conducted among those 18 to 60 years of age to identify probands and their families. Potential probands were identified as those with mean systolic BP between 130 and 160 mm Hg, mean diastolic BP between 85 and 100 mm Hg, and/or no use of antihypertension medication. The probands, along with their spouses, siblings, and offspring, were recruited for participation in the dietary intervention. Details of the eligibility criteria have been presented elsewhere. 8 Among 1,906 eligible participants, 1,860 (97.6%) completed a 7-day low-sodium (51.3 mmol sodium/day) followed by a 7-day high-sodium (307.8 mmol sodium/day) feeding study. We chose the 300 GenSalt participants with the highest and 300 GenSalt participants with the lowest mean arterial pressure (MAP) responses to the high-sodium intervention to participate in the current resequencing study. Institutional review boards at all participating institutions approved the GenSalt study. Written informed consent were obtained from all GenSalt study participants.
Dietary intervention
The study participants received a 7-day low-sodium diet (3 g of sodium chloride or 51.3 mmol of sodium per day) followed by a 7-day high-sodium diet (18 g of sodium chloride or 307.8 mmol of sodium per day). During the period of sodium intervention, dietary potassium intake remained unchanged. Total energy intake was varied according to each participant's baseline energy intake. All study foods were cooked without salt, and prepackaged salt was added to the individual study participant's meal when it was served by the study staff. To ensure study participants' compliance to the intervention program, they were required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. The study participants were instructed to avoid consuming any foods that were not provided by study personnel. Three timed urinary specimens were collected at baseline and at the end of each phase of intervention (days 5, 6, and 7) to monitor each participant's compliance with the dietary sodium intervention. The results from the 24-hour urinary excretions of sodium showed excellent compliance with the study diet. The mean (SD) 24-hour urinary excretions of sodium and potassium were 242.4 (66.7) mmol and 36.9 (9.6) mmol at baseline, 47.5 (16.0) mmol and 31.4 (7.7) mmol during the low-sodium intervention, and 244.3 (37.7) mmol and 35.7 (7.5) mmol during the high-sodium intervention, respectively.
Phenotype measurement
Standard questionnaires were administered by study staff at the baseline exam to collect demographic information, medical history, and lifestyle factors. Systolic BP and diastolic BP were measured 3 times in the morning following a standardized protocol during each of the 3 days of the baseline exam and on days 5, 6, and 7 of each period of the intervention. BP measurements were taken by trained and certified staff using random-zero sphygmomanometers. BP was measured with the participant in a sitting position following 5 minutes of rest. Participants were advised to avoid smoking, consuming alcohol or caffeine, and exercise for at least 30 minutes prior to their measurements. Observers were blinded to the dietary intervention. MAP was calculated as [diastolic BP + (systolic BP − diastolic BP)]/3.
Mean MAP responses to the high-sodium intervention were calculated as the mean of the 9 measures from days 5, 6, and 7 of the high-sodium intervention minus the mean of the 9 measures from days 5, 6, and 7 of the low-sodium intervention. For the resequencing study, we selected the 300 participants with the highest MAP responses to the highsodium intervention (the most salt-sensitive participants) and the 300 participants with the lowest MAP responses to the high-sodium intervention (the most salt-resistant participants).
Candidate gene and single-nucleotide polymorphism selection and sequencing
Seven RAAS genes were selected based on their potential biological effect on BP regulation, including: hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), angiotensin II type 1 receptor (AGTR1), nuclear receptor subfamily 3, group C, member 2 (NR3C2), hydroxysteroid (11-beta) dehydrogenase 2 (HSD11B2), angiotensin I converting enzyme 2 (ACE2), apelin (APLN), and renin-binding protein (RENBP). Functional regions of these 7 RAAS genes were resequenced using the VariantSEQr system (Applied Biosystems; Foster City, CA). Resequencing identified 183 single-nucleotide variants (SNVs) in the selected RAAS genes, including 53 common and low-frequency variants [minor allele frequency (MAF) ≥ 0.01] and 130 rare variants (MAF < 0.01). Variants were updated to the GRCh38 build and then annotated using ANNOVAR software. 25 Haploview software was used to estimate MAF, deviations from Hardy-Weinberg equilibrium and genotyping call rate of identified variants. 26 A total of 9 SNVs with low genotyping call rates (<85%) were excluded, leaving 50 common and low-frequency variants and 124 rare variants for analysis. Characteristics of all identified variants are provided in the Supplementary Table.
Statistical analysis
Salt-sensitive and salt-resistant GenSalt participants were compared on pertinent characteristics with the use of chisquare tests for categorical variables and t-tests for continuous variables.
The aggregate effects of rare variants on BP salt-sensitivity were tested using traditional burden tests. 27, 28 Variants with MAF <0.01 were collapsed within the entire RAAS pathway and within each RAAS gene separately. A binary indicator variable was created to categorize participants based on the presence or absence of any rare variant within the entire RAAS pathway and within each gene. The collapsed indicator variable was then tested for association with BP salt-sensitivity using generalized estimating equations to accommodate family structure while adjusting for the fixed effects of age, gender, field center, and body mass index. A Bonferroni correction for the 8 pathway and gene-based tests was employed, with an alpha threshold of 0.007 used to determine statistical significance.
Additive associations between common and low-frequency variants and BP salt-sensitivity were assessed using generalized estimating equations to account for the nonindependence of family members. Age, gender, field center, and body mass index were adjusted in the multivariable analyses. Since the imputation of variants with MAF ≥0.01 has been shown to be highly accurate, 29 verification analyses were conducted for common and low-frequency variants achieving nominal significance (P < 0.05) in the entire GenSalt sample. When possible, identified variants were imputed in the remaining 1,260 GenSalt participants using the ALL ancestry panel of the 1,000 Genomes Phase I Intergrated Release Version 3 haplotypes and minimac software. 30 For variants not present in the 1,000 Genomes reference panel, unrelated participants with sequencing and genome-wide genotype data were used as the reference panel for imputation in the remaining GenSalt participants. The imputed variants were tested for association with the continuous MAP response to high-sodium phenotype among all 1,860 GenSalt participants. To accommodate the nonindependence of family members and adjust for the fixed effects of age, gender, field center, and body mass index, a mixed linear regression model was employed to assess SNV-salt-sensitivity associations. An alpha threshold of 0.001, corresponding to a Bonferroni correction for testing 50 SNVs, was used to determine significance of variants in the verification analyses.
RESULTS
Salt-sensitive participants were older and more likely to be female than salt-resistant participants ( Table 1) . As expected, baseline BP was higher and BP responses to both the low-and high-sodium interventions were larger for the salt-sensitive vs. salt-resistant participants.
Results from the RAAS pathway and gene-based analyses are shown in Table 2 . A total of 124 rare variants in the RAAS pathway were identified, with the number in each gene ranging from 5 in RENBP to 38 in NR3C2. In the RAAS pathway, rare variant carriers had a 1.55-fold increased odds (95% confidence interval [CI]: 1.15, 2.10) of salt-sensitivity compared to noncarriers (P value = 0.004). While the number of rare variant carriers tended to be higher in salt-sensitive vs. salt-resistant participants across all genes, in gene-based analyses no genes showed significant associations with saltsensitivity after Bonferroni correction for multiple testing. However, the APLN gene did display a nominally significant association with this phenotype (P = 0.04). Carriers of rare APLN variants had a 2.62-fold increased odds (95% CI: 1.05, 6.58) of salt-sensitivity compared to noncarriers.
In single-marker analyses of the 50 common and lowfrequency variants, 6 SNVs including HSD11B2 marker rs932335, AGTR1 marker rs75367686, NR3C2 markers rs1879829 and rs2070951, ACE2 marker rs184874220, and RENBP variant rs78377269, showed nominal associations with the salt-sensitivity phenotypes (P values = 0.05, 0.04, 0.01, 0.03, 0.05, and 0.03, respectively) ( Figure 1) . Five of the 6 identified variants increased risks of salt-sensitivity (Table 3) , with odds ratios (95% CI
rs184874220, and 2.21 (1.10, 4.42) for RENBP variant rs78377269. The minor allele of NR3C2 marker rs1879829 was associated with a 23% decreased odds (95% CI: 5%, 38%) of salt-sensitivity. In verification analyses among all 1,860 GenSalt dietary intervention participants, no variants associated with BP salt-sensitivity after adjustment for multiple testing (Table 4) . However, RENBP marker rs78377269 remained nominally associated with salt-sensitivity (P value = 0.03), with each copy of the minor allele conferring a 1.63 mm Hg (95% CI: 0.16, 3.10) larger MAP response to the dietary sodium intervention.
DISCUSSION
In the first resequencing study of BP salt-sensitivity, aggregate rare variant analysis revealed an association of the RAAS pathway with this complex phenotype. Among GenSalt participants, carriers of rare RAAS pathway variants had a 1.55-fold higher odds of salt-sensitivity compared to noncarriers, a finding which was significant after stringent correction for multiple testing. Although the power of gene-based analyses may have been limited due to the small number of rare variants identified in the selected genes, a nominal association of the APLN gene with salt-sensitivity was identified, with rare APLN variants conferring a 2.22-fold higher odds of salt-sensitivity. Single-marker analyses did not identify any novel common or low-frequency variants associated with BP salt-sensitivity after adjustment for multiple testing. However, a promising nominal association between a low-frequency, missense SNV in the RENBP gene and salt-sensitivity was identified. Among GenSalt sequencing study participants, each minor allele of RENBP marker rs78377269 conferred a 2.21-fold increased odds of salt-sensitivity compared to the major allele at that locus. Findings of the verification analyses of all GenSalt participants were consistent, with each minor allele increasing MAP responses to the high-sodium intervention by 1.63 mm Hg. In aggregate, these findings highlight the RAAS pathway as a potentially important contributor to BP salt-sensitivity. Furthermore, this study presents of the first evidence of a contribution of rare RAAS variants to this complex phenotype. The current analysis implicates rare variants in the RAAS pathway for association with BP salt-sensitivity. The RAAS pathway has long been studied due to its known influence on renal sodium handling. 31 Through a complex cascade of events which can be induced by fluctuations in dietary sodium intake, the RAAS tightly regulates sodium and water homeostasis as well as vascular tone. 22 While we are the first to identify rare variants in this biological system, numerous previous studies have reported associations of common RAAS variants with BP responses to dietary sodium intake. 16, 21, 32 This study demonstrated a higher frequency of rare RAAS variants among salt-sensitive compared to salt-resistant study participants. It is interesting to note that although none of the individual genes showed significant findings in aggregate rare variant analysis, the general trend of a higher frequency of salt-sensitive rare variant carriers compared to salt-resistant rare variant carriers was observed in all genes but the RENBP gene (which had very few rare variants). While the current study was able to detect systemlevel effects of RAAS variants, the analyses may have been underpowered to detect aggregate rare variant effects in individual genes. Larger studies will be needed to identify the individual genes and rare variants contributing to the strong signal detected.
While no significant associations were identified in genebased analyses, a promising nominal association of the APLN gene was identified. To the knowledge of the authors, the current analysis is not only the first study to report a putative association of rare APLN variants in relation to salt-sensitivity but the first to describe any role of the APLN gene in BP response to dietary sodium intake. APLN has been reported to be involved in BP regulation, with previous reports of associations between common variants and both essential hypertension 33 and potassium sensitivity of BP. 34 In this analysis, those carrying rare APLN variants had a 2.6-fold increased odds of high salt-sensitivity compared to those without rare APLN variants. Despite the large effect size observed, the findings failed to achieve statistical significance after correction for multiple testing. While this may be due to the very few rare variants identified in this gene leading to a low-frequency of rare variant carriers, the findings must be interpreted with caution. Exploration of the association of this gene with salt-sensitivity in larger samples is warranted to verify the findings reported by the current analysis. Similar to the gene-based findings, single-marker analyses of common and low-frequency variants did not reveal significant associations with the BP salt-sensitivity phenotype. However, a promising nominal relation between low-frequency, missense RENBP variant rs78377269, and salt-sensitivity was noted. RENBP is thought to exert its influence on BP regulation and sodium handling by binding to and inactivating renin, an important contributor to the RAAS. 35 Single-marker analyses of common RENBP variants have implicated this gene previously in salt-sensitivity of BP. 21 Here, a consistent detrimental influence of the minor allele of rs78377269 was observed in the sequencing study of 600 GenSalt participants and in the verification analyses of all 1,860 GenSalt participants. SNV rs78377269 has a MAF of 1.3% in the Han Chinese population and encodes the substitution of aspartic acid for alanine in exon 8 of the RENBP gene. Although bioinformatics analyses indicated that such a substitution may be tolerated, 36 its encoded structural change to the renin-binding protein is of particular interest. Future studies in larger samples and functional work to confirm these findings are needed.
As the first resequencing study of the BP salt-sensitivity phenotype, the current study has several important strengths. The recruitment of all Han Chinese participants from an isolated region of rural, north China make the analyses robust to population stratification. Compliance to the dietary intervention, as assessed by urinary excretion of sodium and potassium during each intervention period was excellent. Measurement error was reduced by the large number of BP measurements collected for each participant. Stringent quality control procedures were employed during the measurement of BP and other study covariables, conduct of the dietary interventions and marker data cleaning. Furthermore, gold-standard capillary sequencing methods were utilized to identify SNVs in the study population. However, some limitations of this study should also be addressed. Although we aimed to sequence all functional regions of the selected RAAS genes, when mapped to the newest genome build some likely nonfunctional regions (e.g., introns and intergenic areas) were included and some functional regions were missed (e.g., parts of exons and promoters) (see Supplementary Table) . The inclusion of nonfunctional variants and inadvertent exclusion of functional variants may have reduced the power of aggregate rare variant analyses to detect gene-based associations. In addition, the relatively small sample size may have reduced power further. Finally, external replication analyses were not feasible due to the unique phenotype examined in this study. However, for identified low-frequency and common variants, verification analyses were possible through the implementation of imputation methods in the entire sample. Such findings did bolster support for a nominally associated missense RENBP marker.
In summary, we provide the first evidence for a role for rare variants in the etiology of BP salt-sensitivity. Aggregate rare variant analysis identified a significant association of the entire RAAS pathway with BP response to dietary sodium intervention. Furthermore, promising nominal associations between the APLN gene, as well as a possibly functional, missense variant in the RENBP gene, and BP salt-sensitivity were observed. Despite such encouraging results, additional efforts are required. Replication work is needed to confirm these findings. Furthermore, for findings identified through aggregate rare variant analysis methods, research will be needed to pinpoint the causal variants responsible for the observed signals.
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